Breast cancer is less immunogenic than other tumor forms; nonetheless, anti-PD1/PD-L1 drugs have been studied in breast cancer in recent years, specifically in the triple-negative subtype, with promising results when used alone or in combination with other treatments [10]. This evidence concerns the gene CD274 and breast carcinoma.